Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Di Gioia, Sonia ^a   Bianchi, Paolo ^a   Destro, Annarita ^a   Grizzi, Fabio ^a   Malesci, Alberto ^a,c   Laghi, Luigi ^a   Levrero, Massimo ^b   Morabito, Alberto ^c   Roncalli, Massimo ^a,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NORE1A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CELL SPREADING; CELL SUBPOPULATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CELL; LIVER CIRRHOSIS; LIVER HYPERPLASIA; LIVER NODULE; LIVER REGENERATION; LIVER TUMOR; MALE; NODULAR HYPERPLASIA; PHENOMENOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

ADENOMA; ADULT; AGED; AGING; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; FOCAL NODULAR HYPERPLASIA; GENES, TUMOR SUPPRESSOR; HEPATITIS, VIRAL, HUMAN; HEPATOCYTES; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MIDDLE AGED; MONOMERIC GTP-BINDING PROTEINS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 33745088298     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-89     Document Type: Article

References (35)

1. Lerman MI, Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000, 60:6116-6133.
2. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319.
3. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F: Methylation associated inactivation of RASSFIA from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20:1509-1518.
4. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD: Epigenetic inactivation of RASSFIA in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001, 93:691-699.
5. Dammann R, Takahashi T, Pfeifer GP: The CpG island of the novel tumor suppressor gene RASSFIA is intensely methylated in primary small cell lung carcinomas. Oncogene 2001, 20:3563-3567.
6. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER: The candidate tumor suppressor gene, RASSFIA, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 2001, 98:7504-7509.
7. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG: Frequent epigenetic inactivation of RASSFIA in human bladder carcinoma. Cancer Res 2001, 61:6688-6692.
8. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP: High frequency of promoter hypermethylation of RASSFIA in nasopharyngeal carcinoma. Cancer Res 2001, 61:3877-3881.
9. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER: Epigenetic inactivation of the RASSFIA 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001, 61:7277-7281.
10. Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F: RASSFIA promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001, 20:7573-7577.
11. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001, 61:8659-8663.
12. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R: Methylation of the RASSFIA gene in human cancers. Biol Chem 2002, 383:907-914.
13. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ, Santella RM: High frequency of promoter hypermethylation of RASSFIA and p16 and its relationship to aflatoxin BI-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002, 35:85-92.
14. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002, 2:29.
15. Zhong S, Yeo W, Tang MW, Wong N, Lai PB, Johnson PJ: Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 2003, 9:3376-3382.
16. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003, 22:1866-1871.
17. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163:1371-1378.
18. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, Gennari L, Tommasini M, Malesci A, Coggi G: Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002, 36:427-432.
19. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Toyota J, Satoh M, Endo T, Omata M, Imai K: Detection of hypermethylation of the p16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001, 48:372-377.
20. Waki T, Tamura G, Sato M, Motoyama T: Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 2003, 22:4128-4133.
21. Toyota M, Issa JP: CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999, 9:349-357.
22. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J: The putative tumor suppressor RASSFIA homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002, 21:1381-1390.
23. Tommasi S, Dammann R, Jin SG, Zhang Xf XF, Avruch J, Pfeifer GP: RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002, 21:2713-2720.
24. Hesson L, Dallol A, Minna JD, Maher ER, Latif F: NOREIA, a homologue of RASSFIA tumour suppressor gene is inactivated in human cancers. Oncogene 2003, 22:947-954.
25. Destro A, Bianchi P, Alloisio M, Laghi L, Di Gioia S, Malesci A, Cariboni U, Gribaudi G, Bulfamante G, Marchetti A, Bosari S, Infante M, Ravasi G, Roncalli M: K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004, 44:23-32.
26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
27. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996, 6:986-994.
28. Rutledge RG, Cote C: Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res 2003, 31:e93.
29. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988, 239:487-491.
30. Lo YMD, Wong IHN, Zhang J, Tein MSC, Ng MHL, Hjelm NM: Quantitative Analysis of Aberrant p16 Methylation Using Real-Time Quantitative Methylation-specific Polymerase Chain Reaction. Cancer Res 1999, 59:3899-3903.
31. Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
32. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H, Flemming P: Distinct Methylation Patterns of Benign and Malignant Liver Tumors Revealed by Quantitative Methylation Profiling. Clin Cancer Res 2005, 11:3654-3660.
33. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002, 2:29.
34. Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F: Frequent epigenetic inactivation of RASSFIA and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004.
35. Nakagawa H, Nuovo GJ, Zervos EE, Martin EWJ, Salovaara R, Aaltonen LA, de la Chapelle A: Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001, 61:6991-6995.